EUCTR2014-001470-34-GB进行中（未招募）不适用
Pilot institutional study evaluating 5-fluorouracil following radiation therapy in children and young adults with relapsed/refractory ependymoma. - 5-FU in relapsed Ependymoma v1.0
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients aged 1-24 years old at the time of informed consent.
- •- Histological confirmation of ependymoma at the time of initial diagnosis.
- •- Relapsed or progressed disease following previous standard treatment including radiotherapy. N.B.: patients suitable for re-irradiation at the time of relapse might still be eligible for the present study.
- •- Stable neurologic examination.
- •- Measurable disease as per RECIST 1.1.
- •- Life expectancy of = 12 weeks.
- •- Performance status as follows: Lansky scale = 50% for patients <12 years; Karnofsky = 50% for patients =12 years.
- •- Adequate bone marrow function at the time of eligibility assessment, defined as per full blood count on peripheral blood.
- •- Adequate liver function at the time of eligibility assessment, defined as per routine liver function tests on peripheral blood.
- •- Adequate renal function, defined as per routine parameters on peripheral blood and Glomerular Filtration Rate estimated by Schwartz formula.
- •- Adequate cardiac function at the time of eligibility assessment, defined as per previous history, physical examination, and ECG.
- •- Negative pregnancy test in female patients of childbearing potential.
- •- Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- •- Written informed consent/assent prior to enrolment.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 12
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •- The patient must not have received, at the time of eligibility assessment:
- •o any myelosuppressive chemotherapy within 3 weeks (exceptions: 6 weeks if prior nitrosourea, or 1 week if low dose metronomic chemotherapy);
- •o any biological agent within 2 weeks;
- •o focal radiotherapy within 4 weeks or craniospinal radiotherapy within 3 months;
- •o any investigational therapy within 4 weeks. Investigational therapy is defined as any medicinal product that is not approved in the UK for any indication.
- •- Concomitant use of dehydropyrimidine dehydrogenase (DPD) inhibitors, such as brivudin, sorivudin and analogues within the previous 4 weeks.
- •- Patients who have an uncontrolled infection.
- •- Known active viral hepatitis, including Hepatitis A, B or C, or known diagnosis of human immunodeficiency virus (HIV) infection. Viral testing is not mandatory.
- •- Pregnant or lactating females.
- •- Low probability of treatment compliance.
- •- Other severe, acute or chronic, medical or psychiatric condition, or laboratory abnormality, that may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for the study.
研究者
相似试验
已完成
2 期
Randomized phase II/III study of 5-fluorouracil /l-leucovorin vs. 5-fluorouracil /l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G, abbreviation:GC_FL/FLTAX_P2/3)Gastric cancerJPRN-UMIN000010949Japan Clinical Oncology Group (JCOG)330
已完成
不适用
A randomised trial of infusional 5-fluorouracil and concomitant radiotherapy in locally advanced rectal cancer, comparing three and six months of infusional 5-fluorouracilCancer of rectumCancerISRCTN93845533The Royal Marsden NHS Foundation Trust (UK)
已完成
不适用
Phase II randomized trial comparing 5-fluorouracil in continuous infusion and cisplatin (FP) versus leucovorin, bolus 5-fluorouracil and cisplatin (FLP) in metastatic gastric, pancreatic and oesophageal cancerMetastatic gastric, pancreatic and oesophageal cancerOesophagealCancerISRCTN05842222French Federation of Digestive Cancers (Fédération Francophone de la Cancérologie Digestive [FFCD]) (France)232
已完成
不适用
A trial of intraoperative 5-fluorouracil (5-FU) in primary glaucoma surgery: effects on long term intraocular pressure control and disease progressioGlaucomaEye DiseasesISRCTN81872640Medical Research Council (MRC) (UK)367
已完成
2 期
pilot study of intraarterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma patients who do not response to intraarterial 5-fluorouracil/cisplatin combination therapy.advanced hepatocellular caricinomaJPRN-UMIN000002928Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical, Hiroshima University20